



**Supplementary Figure 4. The monthly trend of glomerulonephritis during the COVID-19 pandemic period (after February 2022) in Severance Hospital based on the ARIMA models.** (A) Total, (B) acute tubular injury (AIN), (C) acute interstitial nephritis (ATI), (D) immunoglobulin A nephropathy (IgAN), (E) membranous nephropathy (MN), (F) nonspecific histology, (G) other nephropathies, (H) immune complex-mediated glomerulonephritis (IC-GN), (I) pauci-immune crescentic glomerulonephritis, (J) podocytopathy, and (K) thrombotic microangiopathy (TMA). The blue lines denote the observed value, and the red lines denote the estimated value from optimal ARIMA models. The gray-dotted lines denote February 2022.

ARIMA, autoregressive integrated moving average; COVID-19, coronavirus disease 2019.